Seviteronel is an Orally Active CYP17 Lyase Inhibitor for Triple Negative Breast Cancer Research
As reported, triple negative breast cancer (TNBC) is a heterogeneous cancer subtype lack of estrogen receptor, progesterone receptor, or HER2. Thus, there is still a clinical need for the development…